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Arterial Disease
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Morial Convention Center, Room 260
2:15 p.m.
848-2 Utilizing of the Fibrin Meshwork to Induce 
Neovascularization in Patients With Chronic Limb 
Ischemia: Long-Term Follow-Up
Nicholas N. Kipshidze, Kote Kipiani, Nutsa Beridze, Gary Roubin, Mykola Tsapenko, 
Mohammad Shehzad, Jeffrey W. Moses, Nodar N. Kipshidze, Lenox Hill Heart and 
Vascular Institute and CRF, New York, NY, National Center of Angiology and Vascular 
Surgery, Tbilisi, Georgia
Objectives: We assessed the feasibility and efficacy of fibrin as an angiogenic sub-
stance alone and/or as a carrier for vascular endothelial growth factor (VEGF) in patients
with chronic limb ischemia.
Methods: 23 patients with chronic limb ischemia were randomized for treatment: Group
1(control): 7 patients received only a saline injection; Group 2: 9 received intramuscular
injection of fibrin and Group 3: 7 received the fibrin composition with Deferoxamine and
added VEGF165, The fibrin meshwork was introduced into the popliteal area of the dis-
eased limbs using a dual syringe system (one contained thrombin solution [1mg, 5000U]
and one contained fibrinogen [1 mg, Baxter Hyland Immuno] solution). In group 3, Defer-
oxamine (100 µg) and 500 µg of VEGF165 were added to the fibrinogen solution.
Results: The ankle-brachial index (ABI) in the Group 1 was 0.46 ± 0.12 before beginning
the trial and was 0.41 ± 0.16 at the 3 month follow-up (FU). The ABI in patients treated
with fibrin only increased from 0.43 ± 0.20 to 0.73 ± 0.12 at six months FU (p<0.05 vs.
baseline data and vs. control group). In the Group 3 the ABI increased from 0.49 ± 0.12
to 0.78 ± 0.19 (p<0.05 vs. control). Transcutaneous oxygen pressure (Tc02) increased in
the Group 2 from 20.1 ± 4.4 mmHg to 41.5 ± 3.2 mmHg and in the Group 3 from 19.8 +
4.5 mmHg to 47.8+ 2.6 mmHg at 3 months FU as compared to it decrease from 19.1 ±
3.6 mmHg to 16.3+4.7 mmHg in the control group. In the control group 5 patients had
undergone below the knee amputation at 3-6 month FU. Only 1 patient from the Group 2
had amputation at 5 months FU. At 3 year FU 1 more patient from the Group 2 underwent
below knee amputation. Thus, at 3 year FU clinical improvement was sustained in 6
patients from the Group 2 and in 6 patients from the Group 3.
Conclusion: IM injection of Fibrin is safe and appears to be an efficient method to treat
chronic limb ischemia. These findings indicate that use of fibrin may be a novel and sim-
ple method for inducing therapeutic angiogenesis.
2:30 p.m.
848-3 Estrogen Plus Progestin and the Risk of Peripheral 
Arterial Disease
Judith Hsia, Michael Criqui, Rebecca Rodabough, Helaine Resnick, Jane Kotchen, 
Denise Bonds, Matt Allison, Pat Caralis, Lawrence Phillips, Kamal Masaki, Robert D. 
Langer, George Washington University, Washington, DC
Background: In randomized trials, postmenopausal hormone therapy has had variable
effects on peripheral arterial intima-media thickness. Combination therapy with estrogen
plus progestin (E+P) did not affect peripheral arterial events in women with prior coronary
heart disease. This analysis evaluates the impact of E+P on peripheral arterial events
among generally healthy women in the Women’s Health Initiative randomized trial.
Methods: The Estrogen Plus Progestin trial assigned 16,608 postmenopausal women,
age 50-79 years, to daily conjugated estrogens 0.625 mg with medroxyprogesterone
acetate 2.5 mg or to placebo. Peripheral arterial disease was a prespecified secondary
outcome.
Results: During 5.6 years of follow up, carotid artery disease (0.08%/y), lower extremity
arterial disease (0.06%/y) and abdominal aortic aneurysm (0.02%/y) requiring hospital-
ization were infrequent, and did not differ between treatment groups (HR 0.89, 95% CI
0.63, 1.25). In the two years following randomization, risk of peripheral arterial events
was slightly greater among women assigned to active E+P (HR 1.33 in year 1, HR 1.27 in
year 2), but this difference subsided thereafter (HR 0.85 and 0.87 in years 5 and >6,
respectively); p for trend 0.39. In multivariate analysis, independent predictors of incident
peripheral arterial disease among women assigned to placebo included age, diabetes
(HR 3.96, 95% CI 1.93, 8.10; p<0.001), current smoking (HR 4.65, 95% CI 2.38, 9.09;
p<0.001) and prior peripheral arterial disease (HR 20.26, 95% CI 9.13, 44.97; p<0.001).
Among women assigned to combination hormone therapy, associations were similar
except that prior coronary heart disease, which was reported by 2.4% of women at base-
line, also independently predicted peripheral arterial events (HR 4.13, 95% CI 1.81, 9.41;
p<0.001). Subgroup analysis identified no significant interactions between E+P and
baseline characteristics with regard to peripheral arterial disease risk.
Conclusions: Estrogen plus progestin does not confer protection against peripheral
arterial disease among generally healthy postmenopausal women.
2:45 p.m.
848-4 Noninvasive Characterization of Carotid Plaque 
Inflammation in Humans With FDG-Positron Emission 
Tomography
Ahmed Tawakol, Raymond Q. Migrino, Henry Gewirtz, James E. Muller, Thomas Brady, 
Alan J. Fischman, Massachusetts General Hospital, Boston, MA
Introduction: Atherosclerotic plaques that cause MI and stroke are inflamed. We previ-
ously demonstrated that that positron emission tomography (PET) with 18F-fluorodeoxy-
glucose (FDG) characterizes plaque inflammation in an animal model of atherosclerosis.
Methods: To test the hypothesis, in humans, that plaque inflammation can be character-
ized using FDG-PET, 6 patients with moderate to high-grade carotid stenoses underwent
PET imaging 3 hours after FDG administration (25 mCi). Local uptake of FDG was deter-
mined non-invasively by measuring Standardized Uptake Values (SUV) within the vessel
wall. Thereafter, subjects underwent carotid endarterectomy (CEA), at which time carotid
specimens were collected and examined for macrophage staining. Carotid FDG uptake
(determined by PET, prior to CEA) was subsequently compared to macrophage density
(determined histologically). Results: Moderate to severe carotid inflammation was
observed in the histologic specimens of 3/6 patients. Moreover, FDG uptake, determined
non-invasively prior to CEA (plaque:blood SUV) correlated with histologic evidence of
inflammation, (r=0.80, p<0.001, figure). Conclusions: These preliminary findings sup-
port the hypothesis that carotid plaque inflammation can be characterized non-invasively
by FDG PET. Such metabolic information has potential to contribute to the assessment of
stroke risk from carotid plaques and underscores the utility of metabolic imaging to char-
acterize vascular inflammation in humans. 
3:00 p.m.
848-5 The Impact of Percutaneous Renal Artery 
Revascularization on QT Dispersion in Patients With 
Hypertensive Heart Disease
Adam E. Berman, Patty Uber, Mandeep R. Mehra, Ochsner Clinic Foundation, New 
Orleans, LA
Objective: To evaluate the efficacy of percutaneous renal artery revascularization
(PRAR) on the reduction of indices of ventricular repolarization in homogeneity in
patients with underlying hypertensive heart disease (HHD).
Methods: We retrospectively analyzed all patients who underwent percutaneous renal
artery intervention for angiographically proven renal artery stenosis > 70% over a 4 year
period. We evaluated predictors of benefit from renal artery intervention including age,
CHF, LVH, LVEF, and prior MI. Patients with electrocardiographic evidence of HHD were
compared to similar patients undergoing renal artery intervention without evidence of
HHD. Baseline and follow-up intervals including QRS, QT, QTc, and QT dispersion (QTd)
were measured manually. Patients taking Class I or III antiarrhythmic or angiotensin con-
verting enzyme inhibitor therapy were excluded from the study.
Results: 39 patients were identified with underlying HHD at the time of percutaneous
renal artery intervention (13 males, mean 68±8 yrs). 41% had evidence of prior MI, 33%
had prior CABG, LVEF = .46 ± .16, and 56% had a history of CHF. Mean baseline values
were QRS 105±21 ms, QTc 445 ±33 ms, and QTd 94±32. At 24 month follow up mean
QTd was 46±16 ms (p <.0001).
Conclusions: PRAR in the presence of HHD and renal artery stenosis is associated with
benefits beyond blood pressure control and renal preservation. PRAR may alter indices
of ventricular refractoriness with a greater magnitude than the decrease in LVH would
suggest.
P value R value
Age 0.05
Absolute QTd < 0.0001 0.9
LVH @ baseline 0.02 0.4
CHF 0.05 0.3
